Sage Journals: Discover world-class research

Abstract

The compensatory approach of fatigue argues that it is a state caused by task load. The neuropsychiatric approach argues that fatigue is a trait (like depression), unrelated to environmental challenges. We propose that fatigue is an internal state that can be measured behaviorally only by applying specific cognitive tasks. PubMed was searched for articles concerning the relation between fatigue and cognitive performance or brain atrophy or functional MRI, distinguishing between the following cognitive domains: learning/memory, cognitive speed/selective attention, language, visuospatial processing, working memory, alerting/vigilance. Only tasks assessing alerting/vigilance are strongly related to fatigue. Areas with brain atrophy in fatigue patients overlap with brain regions activated in healthy controls performing alerting/vigilance tasks. Fatigue is not a compensatory state, nor a psychogenic trait. It is a feeling with behavioral effects that seems to be caused by brain atrophy or a neurochemical dysfunction of the alerting/vigilance system.

Keywords

Multiple sclerosis fatigue cognitive testing vigilance attentional systems neuronal networks of attention brain atrophy

Get full access to this article

View all access options for this article.

References

DeLuca

Genova

Hillary

. Neural correlates of cognitive fatigue in multiple sclerosis using functional MRI. J Neurol Sci 2008; 270: 28–39.

Bol

Duits

Hupperts

. The psychology of fatigue in patients with multiple sclerosis: A review. J Psychosom Res 2009; 66: 3–11.

DeLuca

. Fatigue, cognition, and mental effort. In DeLuca

(ed.) Fatigue as a window to the brain. Cambridge: MIT Press, 2005, pp.37–57.

Posner

Petersen

. The attention system of the human brain. Annu Rev Neurosci 1990; 13: 25–42.

Sturm

Willmes

. On the functional neuroanatomy of intrinsic and phasic alertness. Neuroimage 2001; 14: S76–S84.

Spierings

Volkerts

Heitland

. A randomized, rater-blinded, crossover study of the effects of oxymorphone extended release, fed versus fasting, on cognitive performance as tested with CANTAB in opioid-tolerant subjects. Pain Med 2014; 15: 264–271.

Paus

Zatorre

Hofle

. Time-related changes in neural systems underlying attention and arousal during the performance of an auditory vigilance task. J Cogn Neurosci 1997; 9: 392–408.

Calabresi

Castrioto

Di Filippo

. New experimental and clinical links between the hippocampus and the dopaminergic system in Parkinson’s disease. Lancet Neurol 2013; 12: 811–821.

Tiplady

Bowness

Stien

. Selective effects of clonidine and temazepam on attention and memory. J Psychopharmacol 2005; 19: 259–265.

10.

Coull

. Neural correlates of attention and arousal: Insights from electrophysiology, functional neuroimaging and psychopharmacology. Prog Neurobiol 1998; 55: 343–361.

11.

Nutt

Demyttenaere

Janka

. The other face of depression, reduced positive affect: The role of catecholamines in causation and cure. J Psychopharmacol 2007; 21: 461–471.

12.

Papakostas

Nutt

Hallett

. Resolution of sleepiness and fatigue in major depressive disorder: A comparison of bupropion and the selective serotonin reuptake inhibitors. Biol Psychiatry 2006; 60: 1350–1355.

13.

Cooper

Tucker

Papakostas

. Resolution of sleepiness and fatigue: A comparison of bupropion and selective serotonin reuptake inhibitors in subjects with major depressive disorder achieving remission at doses approved in the European Union. J Psychopharmacol 2014; 28: 118–124.

14.

Moss

Simpson

Pelletier

. An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners. Psychooncology 2006; 15: 259–267.

15.

Cullum

Wojciechowski

Pelletier

. Bupropion sustained release treatment reduces fatigue in cancer patients. Can J Psychiatry 2004; 49: 139–144.

16.

Siniscalchi

Gallelli

Tolotta

. Open, uncontrolled, nonrandomized, 9-month, off-label use of bupropion to treat fatigue in a single patient with multiple sclerosis. Clin Ther 2010; 32: 2030–2034.

17.

Pardini

Capello

Krueger

. Reward responsiveness and fatigue in multiple sclerosis. Mult Scler 2013; 19: 233–240.

18.

Bould

Wiles

Potokar

. Does baseline fatigue influence treatment response to reboxetine or citalopram in depression? An open label randomized controlled trial. J Psychopharmacol 2012; 26: 663–669.

19.

Arnold

Crofford

. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004; 50: 2974–2984.

20.

Solaro

Bergamaschi

Rezzani

. Duloxetine is effective in treating depression in multiple sclerosis patients: An open-label multicenter study. Clin Neuropharmacol 2013; 36: 114–116.

21.

Van Ruitenbeek

Vermeeren

Riedel

. Memory in humans is unaffected by central H1-antagonism, while objectively and subjectively measured sedation is increased. Eur Neuropsychopharmacol 2010; 20: 226–235.

22.

Gillson

Richard

Smith

. A double-blind pilot study of the effect of prokarin on fatigue in multiple sclerosis. Mult Scler 2002; 8: 30–35.

23.

Gillson

Wright

DeLack

. Transdermal histamine in multiple sclerosis: Part one—clinical experience. Altern Med Rev 1999; 4: 424–428.

24.

Gaykema

Park

McKibbin

. Lipopolysaccharide suppresses activation of the tuberomammillary histaminergic system concomitant with behavior: A novel target of immune-sensory pathways. Neuroscience 2008; 152: 273–287.

25.

Heesen

Nawrath

Reich

. Fatigue in multiple sclerosis: An example of cytokine mediated sickness behaviour? J Neurol Neurosurg Psychiatry 2006; 77: 34–39.

26.

Flachenecker

Bihler

Weber

. Cytokine mRNA expression in patients with multiple sclerosis and fatigue. Mult Scler 2004; 10: 165–169.

27.

Pokryszko-Dragan

Frydecka

Kosmaczewska

. Stimulated peripheral production of interferon-gamma is related to fatigue and depression in multiple sclerosis. Clin Neurol Neurosurg 2012; 114: 1153–1158.

28.

Möller

Poettgen

Broemel

. Hagil (Hamburg Vigil Study): A randomized placebo-controlled double-blind study with modafinil for treatment of fatigue in patients with multiple sclerosis. Mult Scler 2011; 17: 1002–1009.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.27 MB

0.17 MB

Is there a cognitive signature for MS-related fatigue?

Abstract

Keywords

Get full access to this article

References

Supplementary Material